ENDRA Life Sciences Inc

NASDAQ:NDRAUnited States

[Financial Tables Follow]
ENDRA Life Sciences Inc. Condensed Consolidated Balance Sheets September 30, December 31, Assets 2024 2023 ---------------------------------------- Current Assets (Unaudited) Cash $ 4,745,187 $ 2,833,907 Prepaid expenses 217,120 198,905 Total Current Assets 4,962,307 3,032,812 Non-Current Assets Inventory 2,711,923 2,622,865 Fixed assets, net 80,281 111,782 Right of use assets 229,771 354,091 Prepaid expenses, long term 388,842 626,610 Other assets 5,986 5,986 Total Assets $ 8,379,110 $ 6,754,146 ----------- ----------- Liabilities and Stockholders' Equity ---------------------------------------- Current Liabilities Accounts payable and accrued liabilities $ 626,706 $ 700,754 Lease liabilities, current portion 187,339 173,857 Loans - 28,484 Total Current Liabilities 814,045 903,095 Long Term Debt Lease liabilities 49,823 192,062 Warranty Liability 910,556 - Total Long Term Debt 960,379 192,062 Total Liabilities 1,774,424 1,095,157 ----------- ----------- Stockholders' Equity Series A Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized; 17.488 and 141.397 shares issued and outstanding, respectively - 1 Series B Convertible Preferred Stock, $0.0001 par value; 1,000 shares authorized; no shares issued and outstanding - - Series C Convertible Preferred Stock, $0.0001 par value; 100,000 shares authorized; no shares issued and outstanding - - Common stock, $0.0001 par value; 20,000,000 shares authorized; 522,005 and 5,937 shares issued and outstanding, respectively 52 1 Additional paid in capital 105,893,728 97,583,906 Stock payable 1 5,233 Accumulated deficit (99,289,095) (91,930,152) Total Stockholders' Equity 6,604,686 5,658,989 ----------- ----------- Total Liabilities and Stockholders' Equity $ 8,379,110 $ 6,754,146 ---------------------------------------- ----------- ----------- ENDRA Life Sciences Inc. Condensed Consolidated Statements of Operations (Unaudited) Three Months Three Months Nine Months Nine Months Ended Ended Ended Ended September September September 30, 30, 30, September 30, 2024 2023 2024 2023 Operating Expenses Research and development $ 794,444 $ 1,632,849 $ 2,552,336 $ 4,424,345 Sales and marketing 83,157 243,332 484,769 672,721 General and administrative 631,413 1,252,881 3,483,303 3,965,889 Total operating expenses 1,509,014 3,129,062 6,520,408 9,062,955 ---------- ---------- ---------- ---------- Operating loss (1,509,014) (3,129,062) (6,520,408) (9,062,955) ---------- ---------- ---------- ---------- Other Expenses Other income (expense) 65,528 28,226 72,069 462,241 Warrant expenses (7,323,685) (7,323,685) Changes in fair value of warrant liability 6,413,081 6,413,081 Total other expenses (845,076) 28,226 (838,535) 462,241 ---------- ---------- ---------- ---------- Loss from operations before income taxes (2,354,090) (3,100,836) (7,538,943) (8,600,714) Provision for income taxes - - - - Net Loss $(2,354,090) $(3,100,836) $(7,538,943) $(8,600,714) ---------- ---------- ---------- ---------- Net loss per share -- basic and diluted $ (9.54) $ (706.20) $ (82.14) $ (2,672.98) ---------- ---------- ---------- ---------- Weighted average common shares -- basic and diluted 246,816 4,391 89,592 3,218 ------------------- ---------- ---------- ---------- ----------